Capricor Therapeutics (NASDAQ:CAPR) Earns “Buy” Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $77.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 393.27% from the company’s current price.

Several other research firms have also issued reports on CAPR. Maxim Group lifted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Cantor Fitzgerald upped their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Piper Sandler began coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Up 4.3 %

CAPR stock opened at $15.61 on Thursday. The business has a 50 day moving average of $16.70 and a 200 day moving average of $10.89. The firm has a market cap of $709.79 million, a PE ratio of -14.73 and a beta of 3.98. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CAPR. SG Americas Securities LLC purchased a new stake in Capricor Therapeutics during the 3rd quarter valued at $133,000. The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics during the third quarter valued at $161,000. Sassicaia Capital Advisers LLC bought a new position in Capricor Therapeutics in the third quarter valued at about $192,000. BNP Paribas Financial Markets boosted its position in Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 15,872 shares during the last quarter. Finally, FMR LLC purchased a new position in Capricor Therapeutics in the third quarter worth about $370,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.